Lv11
46 积分 2022-05-01 加入
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
1小时前
待确认
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial
1个月前
已完结
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
1个月前
已完结
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)
1个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1个月前
已完结
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial
2个月前
已完结
肝细胞癌新辅助及转化治疗后疗效病理学评估专家共识（2025版）
2个月前
已完结
原发性肝细胞癌后线规范化用药专家共识
7个月前
已关闭
Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets
7个月前
已关闭
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy
7个月前
已完结
皖公网安备34019202002308
